(Q37280938)

19 August 2017

1 reference

title

Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation (English)

1 reference

19 August 2017

1

Owen A O'Connor

1 reference

19 August 2017

Myron S Czuczman

2

1 reference

19 August 2017

language of work or name

1 reference

1 January 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

49 Suppl 1

1 reference

19 August 2017

page(s)

59-66

1 reference

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Thalidomide and lenalidomide in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802365033

10.1080/10428190802365033

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference